Exhibit 99.1
Amended Loan Schedule to Secured Promissory Note dated November 10, 2022 | |||
between Acura Pharmaceuticals, Inc. and Abuse Deterrent Pharma, LLC | |||
Date | Principal | Aggregated Principal | |
Original Secured Promissory Note | 11/10/2022 | $2,319,279 | $2,319,279 |
Additional loans to be included: | |||
Loan #1 | 12/22/2022 | $250,000 | $2,569,279 |
Loan #2 | 1/19/2023 | $250,000 | $2,819,279 |
Loan #3 | 2/22/2023 | $250,000 | $3,069,279 |
Loan #4 | 3/20/2023 | $250,000 | $3,319,279 |
Loan #5 | 5/19/2023 | $150,000 | $3,469,279 |
Loan #6 | 7/10/2023 | $200,000 | $3,669,279 |
Loan #7 | 7/28/2023 | $250,000 | $3,919,279 |
Loan #8 | 8/30/2023 | $250,000 | $4,169,279 |
Loan #9 | 10/11/2023 | $250,000 | $4,419,279 |
Loan #10 | 12/04/2023 | $250,000 | $4,669,279 |
ACURA PHARMACEUTICALS, INC.
By: /s/ Peter A. Clemens
Peter A. Clemens
Senior Vice President & Chief Financial Officer
Date: December 4, 2023